SH3RF2: A Potential Drug Target and Biomarker for Protein Phosphatase 1 Regulation

Target Name: SH3RF2

NCBI ID: G153769

SH3RF2

SH3RF2: A Potential Drug Target and Biomarker for Protein Phosphatase 1 Regulation

Protein phosphatases are a family of enzymes that play a crucial role in cellular signaling pathways. These enzymes remove phosphate groups from protein targets, thereby regulating their activity and localizing them to specific cellular locations. One of the protein phosphatases is SH3RF2, which is a key regulatory subunit of the protein phosphatase 1 (PP1). The SH3RF2 gene has been well-studied, and its function in PP1 regulation has been extensively reported. In this article, we will discuss the potential implications of SH3RF2 as a drug target and biomarker.

The SH3RF2 gene is located on chromosome 16 at position 11.1 kb, and it encodes a protein with 219 amino acid residues. The protein has a unique structure, with a catalytic core and a distinct N-terminal region that is involved in protein-protein interactions. The SH3RF2 protein functions as a regulatory subunit of PP1, which is a protein that removes phosphate groups from various protein targets.

The SH3RF2 protein has several unique features that make it an attractive drug target. First, it has a clear and well-studied function in PP1 regulation. Second, its function in PP1 regulation can be modulated by small molecules, which provides a means to target the protein and modulate its activity. Third, the SH3RF2 protein is expressed in most tissues and cells, which makes it a potential biomarker for diseases associated with PP1 regulation.

One of the potential benefits of targeting SH3RF2 is its potential to modulate PP1 activity in a variety of cellular processes. For example, SH3RF2 has been shown to regulate the activity of PP1 in cell signaling pathways, including cell division, migration, and invasion. Additionally, SH3RF2 has been shown to play a role in regulating cell survival and proliferation. These functions make SH3RF2 an attractive drug target for diseases associated with uncontrolled cell growth and survival.

Another potential benefit of targeting SH3RF2 is its potential to serve as a biomarker for diseases associated with PP1 regulation. SH3RF2 is expressed in most tissues and cells, which makes it a potential marker for diseases associated with PP1 regulation. For example, SH3RF2 has been shown to be downregulated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Additionally, SH3RF2 has been shown to be involved in the regulation of cellular processes that are affected in these diseases, such as cell migration, invasion, and apoptosis. These functions make SH3RF2 an attractive biomarker for diseases associated with PP1 regulation.

In conclusion, SH3RF2 is a protein with significant potential as a drug target and biomarker for PP1 regulation. Its unique function as a regulatory subunit of PP1 and its expression in most tissues and cells make it an attractive target for small molecules. Additionally, its potential to modulate PP1 activity in various cellular processes and serve as a biomarker for diseases associated with PP1 regulation make it an attractive target for further research.

Protein Name: SH3 Domain Containing Ring Finger 2

Functions: Has E3 ubiquitin-protein ligase activity (PubMed:24130170). Acts as an anti-apoptotic regulator of the JNK pathway by ubiquitinating and promoting the degradation of SH3RF1, a scaffold protein that is required for pro-apoptotic JNK activation (PubMed:22128169). Facilitates TNF-alpha-mediated recruitment of adapter proteins TRADD and RIPK1 to TNFRSF1A and regulates PAK4 protein stability via inhibition of its ubiquitin-mediated proteasomal degradation (PubMed:24130170). Inhibits PPP1CA phosphatase activity (PubMed:19945436, PubMed:19389623)

The "SH3RF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH3RF2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets